Last updated: March 4, 2026
What is NDC 00078-0441?
NDC 00078-0441 identifies Methylprednisolone Acetate injectable suspension, used primarily for allergic reactions, inflammation, and certain autoimmune conditions. It is a corticosteroid with multiple formulations and strengths available.
Market Size and Usage
Manufacturing and Sales Volume
- The drug is available in various forms, including 40 mg/mL and 80 mg/mL vials.
- Annual US sales were approximately $250 million in 2022, reflecting steady demand.
- Main prescribers include hospitals, outpatient clinics, and specialty pharmacies.
- Approximate annual prescriptions: 1.2 million units (based on IMS Health data).
Competitive Landscape
- Key competitors include brands such as Depo-Medrol (Pfizer), Solu-Medrol (Pfizer), and generics from multiple manufacturers.
- Market share for the brand manufacturer ranges from 35-45%; generics hold the remainder.
- Recent patent expirations have increased generic competition, leading to price erosion.
Price Analysis
Current Wholesale Acquisition Cost (WAC)
| Formulation |
Average Price per Vial |
Price Range |
Notes |
| 40 mg/mL (30 mL vial) |
$20 |
$18 - $22 |
Widely used, multiple suppliers |
| 80 mg/mL (30 mL vial) |
$30 |
$27 - $33 |
Higher dose, less common |
Source: Red Book 2023;IMS Health data.
Market Pricing Dynamics
- Generic price erosion: Since patent loss, prices have fallen approximately 20-30% over the past five years.
- Reimbursement trends: Medicaid and Medicare are pushing for lower provider reimbursement rates, directly impacting net prices.
- Supply chain factors: Raw material costs for corticosteroids have been stable, but manufacturing costs have slightly increased due to inflation and regulatory compliance.
Price Projections (Next 3-5 Years)
| Year |
Estimated Price per Vial |
Key Factors |
| 2024 |
$17 - $19 |
Saturated generic market, moderate volume growth |
| 2025 |
$15 - $18 |
Increased competition, continued price pressure |
| 2026 |
$14 - $17 |
Further generic adoption, healthcare reforms |
| 2027 |
$13 - $16 |
Potential new formulation or biosimilar entry |
| 2028 |
$12 - $15 |
Market normalization, cost containment measures |
Note: Prices assume continued generic competition and typical healthcare reimbursement trend adjustments.
Regulatory and Patent Context
- The original patent for Depo-Medrol expired in 1997; subsequent patents have expired or been invalidated.
- FDA approval processes permit generic manufacturers to enter the space freely.
- No current patent barriers limit new competitors till at least 2025.
Future Market Drivers
Increased Adoption in Certain Indications
- Growth in autoimmune disorder treatments can expand usage.
- Off-label uses for complex inflammatory conditions contribute to demand.
Potential Impact of Biosimilars and Alternatives
- No biosimilar exists yet for methylprednisolone.
- The rise of oral corticosteroids or biologics may influence injectable corticosteroid demand.
Reimbursement and Policy Changes
- CMS policies favor lower drug prices.
- Medicaid prior authorization can limit high-priced formulations, favoring generics.
Summary of Investment and R&D Implications
- The market is mature with high generic penetration.
- Price erosion diminishes profit margins for original formulators.
- Opportunities lie in new formulations, delivery mechanisms, or biosimilars, which are currently absent.
Key Takeaways
- The 2022 US market for NDC 00078-0441 stood at roughly $250 million.
- Wholesale prices have declined by about 20-30% over five years, with further reductions projected.
- Market saturation and reimbursement pressures suggest prices will stabilize around $12-$15 per vial by 2028.
- Competition from generics limits pricing power; regulatory pathways favor market entry.
- No current biosimilars or next-generation formulations threaten the existing market.
FAQs
1. How does pricing vary between brands and generics?
Generics are priced approximately 20-30% lower than branded formulations, with minimal variation across manufacturers due to market saturation.
2. What factors could reverse the price decline trend?
Introduction of biosimilars, new formulations with better delivery, or regulatory changes could stabilize or increase prices.
3. What are the key market growth opportunities?
Expansion in autoimmune and inflammatory indications, as well as innovations in drug delivery, may provide growth avenues.
4. How does healthcare policy impact market dynamics?
Policies aimed at controlling costs, such as CMS reimbursement adjustments, contribute to downward price pressure.
5. Are there risks related to supply chain or raw materials?
Supply disruptions or raw material cost fluctuations can impact production costs but currently pose minimal risk.
References
- Red Book. (2023). Pharmaceutical pricing data.
- IMS Health. (2022). US drug utilization insights.
- U.S. Food and Drug Administration (FDA). (2023). Drug approvals and patent database.
- Statista. (2022). US corticosteroid market statistics.
- CMS.gov. (2023). Reimbursement policies and updates.
